首页> 外文OA文献 >EZH2 Inhibitor Efficacy in Non-Hodgkin’s Lymphoma Does Not Require Suppression of H3K27 Monomethylation

【2h】

EZH2 Inhibitor Efficacy in Non-Hodgkin’s Lymphoma Does Not Require Suppression of H3K27 Monomethylation

机译：非霍奇金淋巴瘤中的EZH2抑制剂功效不需要抑制H3K27单甲基化

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Bradley William D.; Arora Shilpi; Busby Jennifer; Balasubramanian Srividya; Gehling Victor S.; Nasveschuk Christopher G.; Vaswani Rishi G.; Yuan Chih-Chi; Hatton Charlie; Zhao Feng; Williamson Kaylyn E.; Iyer Priyadarshini; Méndez Jacqui; Campbell Robert; Cantone Nico; Garapaty-Rao Shivani; Audia James E.; Cook Andrew S.; Dakin Les A.; Albrecht Brian K.; Harmange Jean-Christophe; Daniels Danette L.; Cummings Richard T.; Bryant Barbara M.; Normant Emmanuel; Trojer Patrick;
展开▼
作者单位

展开▼
年度 2014
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. EZH2 Inhibitor Efficacy in Non-Hodgkin’s Lymphoma Does Not Require Suppression of H3K27 Monomethylation [J] . William D. Bradley, Shilpi Arora, Jennifer Busby, Chemistry & biology . 2014,第11期

机译：非霍奇金淋巴瘤中的EZH2抑制剂功效不需要抑制H3K27单甲基化
2. EZH2 inhibitors abrogate upregulation of trimethylation of H3K27 by CDK9 inhibitors and potentiate its activity against diffuse large B-cell lymphoma [J] . Shao Xie, Fan Wei, Yi-ming Sun, Haematologica . 2020,第4期

机译：EZH2抑制剂通过CDK9抑制剂删除了H3K27的三甲基化物，并使其对弥漫性大B细胞淋巴瘤的活性
3. ZLD1122, a novel EZH2 and EZH1 small molecular inhibitor, blocks H3K27 methylation and diffuse large B cell lymphoma cell growth [J] . Gao Tiantao, Zhang Lidan, Zhu Yongxia, RSC Advances . 2016,第34期

机译：ZLD1122，一种新型EZH2和EZH1小分子抑制剂，阻断H3K27甲基化和弥漫性大B细胞淋巴瘤细胞生长
4. Development of Single Domain Antibodies for Diagnosis and Treatment of Naturally Occurring Canine Lymphoma: An Animal Model for Human Non-Hodgkin Lymphoma [C] . Joana Dias, Solange Gil, Belmira Carrapico, PEGS . 2015

机译：天然犬淋巴瘤诊断和治疗单结构域抗体的发展：人非霍奇金淋巴瘤的动物模型
5. Risk of Depressive or Anxiety Disorders in Commercially Insured Patients with Non-Hodgkin Lymphoma (NHL) in the US: A Retrospective Analysis [D] . Sun, Lucille 2017

机译：美国非霍奇金淋巴瘤（NHL）商业保险患者发生抑郁或焦虑症的风险：回顾性分析
6. EZH2 inhibitors abrogate upregulation of trimethylation of H3K27 by CDK9 inhibitors and potentiate its activity against diffuse large B-cell lymphoma [O] . Shao Xie, Fan Wei, Yi-ming Sun, 2020

机译：EZH2抑制剂消除了CDK9抑制剂对H3K27三甲基化的上调作用并增强了其对弥漫性大B细胞淋巴瘤的活性
7. Discovery of EBI-2511: A Highly Potent and Orally Active EZH2 Inhibitor for the Treatment of Non-Hodgkin’s Lymphoma [O] . Biao Lu, Xiaodong Shen, Lei Zhang, 2018

机译：EBI-2511的发现：一种高效且口服活性的EZH2抑制剂，用于治疗非霍奇金淋巴瘤

EZH2 Inhibitor Efficacy in Non-Hodgkin’s Lymphoma Does Not Require Suppression of H3K27 Monomethylation

著录项

引文网络

相似文献

相关主题

期刊订阅